β-Lapachone (Synonyms: ARQ-501; NSC-26326)

Name: β-Lapachone
Brand: MedChemExpress
SKU: HY-13555
Rating: 5.0 (10 reviews)

Cat. No.: HY-13555 Purity: 99.99%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

β-Lapachone (ARQ-501;NSC-26326) is a naturally occurring O-naphthoquinone, acts as a topoisomerase I inhibitor, and induces apoptosis by inhibiting cell cycle progression.

For research use only. We do not sell to patients.

β-Lapachone Chemical Structure

CAS No. : 4707-32-8

Size	Price	Stock	Quantity
Solution
10 mM * 1 mL in Ethanol	USD 88	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 79	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 277	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 387	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

10 Publications Citing Use of MCE β-Lapachone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

View All Isoforms

IDO1 IDO2 IDO

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

β-Lapachone (ARQ-501;NSC-26326) is a naturally occurring O-naphthoquinone, acts as a topoisomerase I inhibitor, and induces apoptosis by inhibiting cell cycle progression.

IC₅₀ & Target^[1]

Topoisomerase I

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	IC₅₀	> 0.8 μM Compound: 13	Cytotoxicity against paclitaxel-resistant human 1A9 cells after 3 days by SRB assay Cytotoxicity against paclitaxel-resistant human 1A9 cells after 3 days by SRB assay	[PMID: 15217280]
1A9	IC₅₀	0.8 μM Compound: 13	Cytotoxicity against human 1A9 cells after 3 days by SRB assay Cytotoxicity against human 1A9 cells after 3 days by SRB assay	[PMID: 15217280]
A2780	GI₅₀	1.1 μM Compound: 5	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
A549	IC₅₀	> 10 μM Compound: Beta-lapachone	Activation of NQO1 in human A549 cells assessed as decrease in cell survival incubated for 2 hrs measured after 7 days in presence of NQO1 inhibitor dicoumarol by Hoechst 33258 staining based assay Activation of NQO1 in human A549 cells assessed as decrease in cell survival incubated for 2 hrs measured after 7 days in presence of NQO1 inhibitor dicoumarol by Hoechst 33258 staining based assay	[PMID: 27341379]
A549	IC₅₀	0.8 μM Compound: Beta-Lapachone	Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay	[PMID: 26883150]
A549	GI₅₀	0.8 μM Compound: beta-Lapachone	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22819765]
A549	IC₅₀	1.5 μM Compound: 13	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 15217280]
A549	IC₅₀	1.96 μM Compound: 5	Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay	[PMID: 32044231]
A549	IC₅₀	16 μM Compound: Beta-lap	Cytotoxicity against human DPP-resistant A549 cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human DPP-resistant A549 cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33984806]
A549	CC₅₀	2.09 μM Compound: 30	Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay	[PMID: 33333397]
A549	IC₅₀	25 μM Compound: 1, beta-Lap	Cytotoxicity against human A549 cells after 72 hrs by MTT assay in presence of NQO1 inhibitor dicoumarol Cytotoxicity against human A549 cells after 72 hrs by MTT assay in presence of NQO1 inhibitor dicoumarol	[PMID: 25677663]
A549	IC₅₀	29 μM Compound: Beta-lap	Cytotoxicity against NQO1-deficient human A549 cells assessed as reduction in cell viability pretreated with DIC followed by compound addition and incubated for 72 hrs by MTT assay Cytotoxicity against NQO1-deficient human A549 cells assessed as reduction in cell viability pretreated with DIC followed by compound addition and incubated for 72 hrs by MTT assay	[PMID: 33984806]
A549	IC₅₀	3 μM Compound: Beta-lap	Substrate activity at NQO1 in human A549 cells assessed as NQO1-mediated two-electron reduction of compound by measuring cell growth inhibition treated for 24 hrs measured after 72 hrs by MTT assay Substrate activity at NQO1 in human A549 cells assessed as NQO1-mediated two-electron reduction of compound by measuring cell growth inhibition treated for 24 hrs measured after 72 hrs by MTT assay	[PMID: 28214631]
A549	IC₅₀	3.1 μM Compound: Beta-lap	Cytotoxicity against human A549 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30508483]
A549	IC₅₀	3.32 μM Compound: Beta-lap	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
A549	GI₅₀	3.32 μM Compound: Beta-lap	Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32464425]
A549	IC₅₀	3.4 μM Compound: Beta-lapachone	Activation of NQO1 in human A549 cells assessed as decrease in cell survival incubated for 2 hrs measured after 7 days by Hoechst 33258 staining based assay Activation of NQO1 in human A549 cells assessed as decrease in cell survival incubated for 2 hrs measured after 7 days by Hoechst 33258 staining based assay	[PMID: 27341379]
A549	IC₅₀	3.7 μM Compound: 1; beta-lap	Cytotoxicity against human A549 cells expressing NQO1 after 2 hrs by MTT assay Cytotoxicity against human A549 cells expressing NQO1 after 2 hrs by MTT assay	[PMID: 26803578]
A549	EC₅₀	4.21 μM Compound: 4	Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
A549	IC₅₀	5.7 μM Compound: beta-lap	Cytotoxicity against NQO-1 rich human A549 cells assessed as inhibition of cell viability after 2 hrs by MTT assay Cytotoxicity against NQO-1 rich human A549 cells assessed as inhibition of cell viability after 2 hrs by MTT assay	[PMID: 24874653]
A549	IC₅₀	5.7 μM Compound: Beta-lap	Cytotoxicity against human A549 cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33984806]
A549	IC₅₀	6 μM Compound: Beta-lap	Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay	[PMID: 32682198]
A549	GI₅₀	6 μM Compound: Beta-lap	Cytotoxicity against human A549 cells assessed as reduction in cell growth pretreated for 1 hr with NQO1 inhibitor, dicoumarol followed by incubation with compound for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth pretreated for 1 hr with NQO1 inhibitor, dicoumarol followed by incubation with compound for 48 hrs by MTT assay	[PMID: 32464425]
A549	GI₅₀	6.19 μM Compound: Beta-lap	Cytotoxicity against human A549 cells assessed as reduction in cell growth pretreated for 1 hr with ROS scavenger, N-acetyl cysteine followed by incubation with compound for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth pretreated for 1 hr with ROS scavenger, N-acetyl cysteine followed by incubation with compound for 48 hrs by MTT assay	[PMID: 32464425]
A549	IC₅₀	7 μM Compound: 1, beta-Lap	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25677663]
A549/TR	IC₅₀	1.9 μM Compound: Beta-lap	Cytotoxicity against human A549/TR cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549/TR cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30508483]
A549/TR	IC₅₀	11 μM Compound: Beta-lap	Cytotoxicity against human A549/Taxol cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549/Taxol cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33984806]
B16-F10	IC₅₀	0.3 μM Compound: Beta-Lapachone	Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26883150]
BT-549	GI₅₀	11.4 μM Compound: 10	Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
CAKI-1	IC₅₀	> 5 μM Compound: 13	Cytotoxicity against human Caki1 cells after 3 days by SRB assay Cytotoxicity against human Caki1 cells after 3 days by SRB assay	[PMID: 15217280]
CAL-51	GI₅₀	8.3 μM Compound: 10	Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
DU-145	IC₅₀	7.4 nM Compound: 10	Anticancer activity against human DU145 cells after 72 hrs by XTT assay Anticancer activity against human DU145 cells after 72 hrs by XTT assay	[PMID: 18829316]
Erythrocyte	EC₅₀	> 50 μg/mL Compound: 1	Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry	[PMID: 19947600]
HaCaT	IC₅₀	0.9 μM Compound: beta-lapachone	Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay	[PMID: 28410493]
HaCaT	IC₅₀	0.9 μM Compound: beta-lapachone	Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy	[PMID: 24964246]
HaCaT	IC₅₀	0.9 μM Compound: beta-lapachone	Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy	[PMID: 22845014]
HBL-100	GI₅₀	0.38 μM Compound: 1b, ARQ 501, beta-lapachone	Growth inhibition of human HBL100 cells by SRB assay Growth inhibition of human HBL100 cells by SRB assay	[PMID: 22560628]
HBL-100	GI₅₀	0.69 μM Compound: 5	Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HCC1954	GI₅₀	31.8 μM Compound: 10	Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HCT-116	IC₅₀	0.87 μM Compound: Beta-lapachone	Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
HCT-116	IC₅₀	0.87 μM Compound: beta-lap	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
HCT-116	IC₅₀	0.97 μM Compound: beta-Lapachone	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
HCT-116	GI₅₀	12.9 μM Compound: 10	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HCT-8	IC₅₀	0.2 μg/mL Compound: 2b, nor-beta-lapachone	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 17827021]
HCT-8	IC₅₀	0.83 μM Compound: b-lapachone	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 21115213]
HCT-8	IC₅₀	0.83 μM Compound: 1	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19947600]
HCT-8	IC₅₀	0.95 μM Compound: beta-lap	Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
HEK293	IC₅₀	25.31 μM Compound: 3b	Antiproliferative activity against HEK293 cells after 48 hrs by SRB assay Antiproliferative activity against HEK293 cells after 48 hrs by SRB assay	[PMID: 28094224]
HeLa	GI₅₀	0.81 μM Compound: 5	Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HeLa	GI₅₀	1 μM Compound: 1b, ARQ 501, beta-lapachone	Growth inhibition of human HeLa cells by SRB assay Growth inhibition of human HeLa cells by SRB assay	[PMID: 22560628]
HeLa	IC₅₀	1 μM Compound: 31	Inhibition of IDO1 in human IFN-gamma induced HeLa cells assessed as reduction in L-kynurenine formation incubated for 5 hrs Inhibition of IDO1 in human IFN-gamma induced HeLa cells assessed as reduction in L-kynurenine formation incubated for 5 hrs	[PMID: 32055299]
HeLa	IC₅₀	1 μM Compound: beta-Lapachone	Inhibition of IDO1 in IFNgamma-induced human HeLa cells incubated for 5 hrs by Ehrlich's reagent based assay Inhibition of IDO1 in IFNgamma-induced human HeLa cells incubated for 5 hrs by Ehrlich's reagent based assay	[PMID: 31525930]
HeLa	GI₅₀	4.6 μM Compound: beta-Lapachone	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 22819765]
HepG2	CC₅₀	2.09 μM Compound: 30	Cytotoxicity against human HepG2 cells incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 24 hrs by MTT assay	[PMID: 33333397]
HepG2	IC₅₀	2.83 μM Compound: Beta-lap	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
HepG2	GI₅₀	2.83 μM Compound: Beta-lap	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32464425]
HepG2	GI₅₀	6.21 μM Compound: Beta-lap	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth pretreated for 1 hr with ROS scavenger, N-acetyl cysteine followed by incubation with compound for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth pretreated for 1 hr with ROS scavenger, N-acetyl cysteine followed by incubation with compound for 48 hrs by MTT assay	[PMID: 32464425]
HepG2	GI₅₀	6.3 μM Compound: Beta-lap	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth pretreated for 1 hr with NQO1 inhibitor, dicoumarol followed by incubation with compound for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth pretreated for 1 hr with NQO1 inhibitor, dicoumarol followed by incubation with compound for 48 hrs by MTT assay	[PMID: 32464425]
HL-60	IC₅₀	0.27 μM Compound: 15	Cytotoxicity against human promyelocytic leukemia HL60 cell line by MTT assay Cytotoxicity against human promyelocytic leukemia HL60 cell line by MTT assay	[PMID: 17249647]
HL-60	IC₅₀	0.4 μg/mL Compound: 2b, nor-beta-lapachone	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 17827021]
HL-60	IC₅₀	1.57 μM Compound: Beta-lapachone	Cytotoxicity against NQO1-deficient human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NQO1-deficient human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
HL-60	IC₅₀	1.57 μM Compound: beta-lap	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
HL-60	IC₅₀	1.65 μM Compound: beta-Lapachone	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
HL-60	IC₅₀	1.65 μM Compound: b-lapachone	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 21115213]
HL-60	IC₅₀	1.65 μM Compound: 1	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19947600]
HOS	IC₅₀	1.4 μM Compound: 13	Cytotoxicity against human HOS cells after 3 days by SRB assay Cytotoxicity against human HOS cells after 3 days by SRB assay	[PMID: 15217280]
Hs 683	IC₅₀	0.4 μM Compound: Beta-Lapachone	Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay	[PMID: 26883150]
Hs 683	GI₅₀	0.4 μM Compound: beta-Lapachone	Antiproliferative activity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22819765]
J774.A1	IC₅₀	> 200 μg/mL Compound: 1a; beta-lap	Cytotoxicity against mouse J774.A1 cells measured after 24 hrs by resazurin based assay Cytotoxicity against mouse J774.A1 cells measured after 24 hrs by resazurin based assay	[PMID: 31378595]
Jurkat	IC₅₀	1.9 μM Compound: 4a	Inhibition of MALT1 in human Jurkat cell lysate preincubated for 2 hrs followed by addition of 25 uM Ac-LRSR-AMC substrate for 3 hrs by fluorescence based assay Inhibition of MALT1 in human Jurkat cell lysate preincubated for 2 hrs followed by addition of 25 uM Ac-LRSR-AMC substrate for 3 hrs by fluorescence based assay	[PMID: 26496175]
Jurkat	GI₅₀	6.1 μM Compound: beta-Lapachone	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 22819765]
K562	IC₅₀	1.6 μM Compound: 3	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 30003778]
K562	IC₅₀	4 μM Compound: beta-Lapachone	Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay	[PMID: 24775915]
K562	GI₅₀	41 μM Compound: 10	Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
KB	IC₅₀	1 μM Compound: 13	Cytotoxicity against camptothecin-resistant human KB cells after 3 days by SRB assay Cytotoxicity against camptothecin-resistant human KB cells after 3 days by SRB assay	[PMID: 15217280]
KB	IC₅₀	1.2 μM Compound: 13	Cytotoxicity against human KB cells after 3 days by SRB assay Cytotoxicity against human KB cells after 3 days by SRB assay	[PMID: 15217280]
KB	IC₅₀	1.8 μM Compound: 13	Cytotoxicity against etoposide-resistant human KB cells after 3 days by SRB assay Cytotoxicity against etoposide-resistant human KB cells after 3 days by SRB assay	[PMID: 15217280]
L02	IC₅₀	11.9 μM Compound: Beta-lap	Cytotoxicity against NQO1 deficient human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NQO1 deficient human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30508483]
L02	IC₅₀	4.54 μM Compound: Beta-lap	Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
L02	GI₅₀	4.54 μM Compound: Beta-lap	Cytotoxicity against human L02 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32464425]
L02	IC₅₀	9.6 μM Compound: Beta-lap	Cytotoxicity against NQO1-deficient human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against NQO1-deficient human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33984806]
LLC-PK1	CC₅₀	2.09 μM Compound: 30	Cytotoxicity against human LLC-PK1 cells incubated for 24 hrs by MTT assay Cytotoxicity against human LLC-PK1 cells incubated for 24 hrs by MTT assay	[PMID: 33333397]
LoVo	IC₅₀	0.3 μM Compound: Beta-Lapachone	Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 26883150]
LoVo	GI₅₀	0.3 μM Compound: beta-Lapachone	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22819765]
MCF7	IC₅₀	0.5 μM Compound: Beta-Lapachone	Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay	[PMID: 26883150]
MCF7	IC₅₀	0.71 μM Compound: 5	Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay	[PMID: 32044231]
MCF7	IC₅₀	0.8 μM Compound: 13	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 15217280]
MCF7	GI₅₀	12.2 μM Compound: 10	Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MCF7	GI₅₀	4.17 μM Compound: Beta-lap	Cytotoxicity against NQO1-rich human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against NQO1-rich human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 32464425]
MCF7	EC₅₀	9.96 μM Compound: 4	Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
MDA-MB-231	IC₅₀	1.39 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay	[PMID: 32044231]
MDA-MB-231	IC₅₀	4.3 μM Compound: 3	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 30003778]
MDA-MB-435	IC₅₀	0.06 μg/mL Compound: 2b, nor-beta-lapachone	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 17827021]
MDA-MB-435	IC₅₀	0.25 μM Compound: Beta-lapachone	Cytotoxicity against human MDA-MB-435 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
MDA-MB-435	IC₅₀	0.25 μM Compound: beta-lap	Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
MDA-MB-435	IC₅₀	0.25 μM Compound: b-lapachone	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 21115213]
MDA-MB-435	IC₅₀	0.25 μM Compound: 1	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 19947600]
MDCK	IC₅₀	13.5 μM Compound: beta-lap	Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
MOLM-13	GI₅₀	34.5 μM Compound: 10	Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MOLT-4	IC₅₀	0.78 μM Compound: beta-lap	Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
MRC5	CC₅₀	2.09 μM Compound: 30	Cytotoxicity against human MRC5 cells incubated for 24 hrs by MTT assay Cytotoxicity against human MRC5 cells incubated for 24 hrs by MTT assay	[PMID: 33333397]
MV4-11	GI₅₀	70.1 μM Compound: 10	Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
NCI-H596	IC₅₀	23 μM Compound: beta-lap	Cytotoxicity against NQO-1 deficient human NCI-H596 cells assessed as inhibition of cell viability after 2 hrs by MTT assay Cytotoxicity against NQO-1 deficient human NCI-H596 cells assessed as inhibition of cell viability after 2 hrs by MTT assay	[PMID: 24874653]
NCI-H596	IC₅₀	27 μM Compound: Beta-lap	Cytotoxicity against NQO1-deficient human NCI-H596 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against NQO1-deficient human NCI-H596 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33984806]
NCI-H596	IC₅₀	5.06 μM Compound: Beta-lap	Antiproliferative activity against human NCI-H596 cells measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H596 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
OCI-Ly3	IC₅₀	4 μM Compound: 4a	Antiproliferative activity against human OCI-LY3 cells after 48 hrs by MTT assay Antiproliferative activity against human OCI-LY3 cells after 48 hrs by MTT assay	[PMID: 26496175]
OVCAR-3	IC₅₀	1.9 μM Compound: beta-lap	Cytotoxicity against human OVCAR3 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR3 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
OVCAR-8	IC₅₀	1.16 μM Compound: beta-Lapachone	Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
OVCAR-8	IC₅₀	1.16 μM Compound: Beta-lapachone	Cytotoxicity against human OVCAR8 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
OVCAR-8	IC₅₀	1.16 μM Compound: beta-lap	Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
PBMC	IC₅₀	> 20.6 μM Compound: b-lapachone	Cytotoxicity against human PBMC cells after 72 hrs by Alamar Blue assay Cytotoxicity against human PBMC cells after 72 hrs by Alamar Blue assay	[PMID: 21115213]
PBMC	IC₅₀	> 20.6 μM Compound: 1	Cytotoxicity against human PBMC after 72 hrs by alamar blue assay Cytotoxicity against human PBMC after 72 hrs by alamar blue assay	[PMID: 19947600]
PBMC	IC₅₀	> 20.6 μM Compound: beta-Lapachone	Cytotoxicity against human PBMC cells after 72 hrs by MTT assay Cytotoxicity against human PBMC cells after 72 hrs by MTT assay	10.1039/C4MD00371C
PBMC	IC₅₀	> 20.63 μM Compound: Beta-lapachone	Cytotoxicity against NQO1-deficient human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NQO1-deficient human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
PBMC	IC₅₀	> 20.63 μM Compound: beta-lap	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
PBMC	IC₅₀	2.1 μM Compound: 14, beta-Lapachone	Cytotoxicity against human PBMC after 72 hrs by alamar blue assay Cytotoxicity against human PBMC after 72 hrs by alamar blue assay	[PMID: 20378360]
PC-3	IC₅₀	< 0.01 μM Compound: Beta-Lapachone	Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay	[PMID: 26883150]
PC-3	GI₅₀	0.01 μM Compound: beta-Lapachone	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22819765]
PC-3	EC₅₀	1.13 μM Compound: 4	Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
PC-3	IC₅₀	1.65 μM Compound: Beta-lapachone	Cytotoxicity against human PC3 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
PC-3	IC₅₀	1.65 μM Compound: beta-lap	Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
PC-3M	IC₅₀	1.82 μM Compound: beta-lap	Cytotoxicity against human PC3M cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3M cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
Peritoneal macrophage cell	CC₅₀	0.79 μM Compound: beta-Lapachone	Cytotoxicity against Swiss mouse peritoneal macrophages after 24 hrs by MTT assay Cytotoxicity against Swiss mouse peritoneal macrophages after 24 hrs by MTT assay	[PMID: 23535320]
Raji	IC₅₀	210.3 μM Compound: 4	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells after 48 hrs by immunofluorescence technique Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells after 48 hrs by immunofluorescence technique	[PMID: 19674905]
RAW264.7	IC₅₀	0.47 μM Compound: beta-LAPA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23232148]
RAW264.7	IC₅₀	4.06 μM Compound: beta-LAPA	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against mouse RAW264.7 cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 23232148]
SF-295	IC₅₀	0.22 μg/mL Compound: 2b, nor-beta-lapachone	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 17827021]
SF-295	IC₅₀	0.91 μM Compound: beta-Lapachone	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
SF-295	IC₅₀	0.91 μM Compound: b-lapachone	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 21115213]
SF-295	IC₅₀	0.91 μM Compound: 1	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 19947600]
SF-295	IC₅₀	0.95 μM Compound: Beta-lapachone	Cytotoxicity against human SF295 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SF295 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
SF-295	IC₅₀	0.95 μM Compound: beta-lap	Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
SK-MEL-28	IC₅₀	0.6 μM Compound: Beta-Lapachone	Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 26883150]
SK-MEL-28	GI₅₀	0.6 μM Compound: beta-Lapachone	Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22819765]
SW1573	GI₅₀	0.76 μM Compound: 5	Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
SW1573	GI₅₀	0.84 μM Compound: 1b, ARQ 501, beta-lapachone	Growth inhibition of human SW1573 cells by SRB assay Growth inhibition of human SW1573 cells by SRB assay	[PMID: 22560628]
T47D	GI₅₀	2.3 μM Compound: 5	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
U-373MG ATCC	IC₅₀	0.4 μM Compound: Beta-Lapachone	Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay	[PMID: 26883150]
U-373MG ATCC	GI₅₀	0.4 μM Compound: beta-Lapachone	Antiproliferative activity against human U373 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human U373 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22819765]
U-87MG ATCC	IC₅₀	2 μM Compound: 13	Cytotoxicity against human U87MG cells after 3 days by SRB assay Cytotoxicity against human U87MG cells after 3 days by SRB assay	[PMID: 15217280]
Vero	CC₅₀	< 3.1 μM Compound: 1	Cytotoxicity against african green monkey Vero cells after 72 hrs by spectrophotometric analysis Cytotoxicity against african green monkey Vero cells after 72 hrs by spectrophotometric analysis	[PMID: 22795899]
WiDr	GI₅₀	2 μM Compound: 1b, ARQ 501, beta-lapachone	Growth inhibition of human WiDr cells by SRB assay Growth inhibition of human WiDr cells by SRB assay	[PMID: 22560628]
WiDr	GI₅₀	2 μM Compound: 5	Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]

In Vitro

β-Lapachone is a topoisomerase I inhibitor. β-Lapachone (25 μM) inhibits camptothecin-induced DNA cleavage^[1].
β-Lapachone (10-40 μM) significantly reduces the colony-forming ability of CHO cells, and is cytotoxic in S phase. β-Lapachone at above 10 μM, causes a heavy DNA-strand breaks in CHO cells^[2].
β-Lapachone (10 μM) suppresses JCPyV replication in IMR-32 cells. β-Lapachone (1.0?μM) potently affects JCPyV propagation in JCI cells. β-Lapachone (0.01-0.1 μM) inhibits VP1 production in JCI cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

β-Lapachone (0.066%) ameliorates cisplatin-induced renal injury and when in combination with cisplatin, the affect is more significant in mice. β-Lapachone increases Mre11-Rad50-Nbs1 (MRN) complex expression in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

242.27

Formula

C₁₅H₁₄O₃

CAS No.

4707-32-8

Appearance

Solid

Color

Brown to red

SMILES

O=C(C1=C2OC(C)(C)CC1)C(C3=C2C=CC=C3)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (103.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 8.33 mg/mL (34.38 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.1276 mL	20.6381 mL	41.2763 mL
5 mM	0.8255 mL	4.1276 mL	8.2553 mL
10 mM	0.4128 mL	2.0638 mL	4.1276 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 20% SBE-β-CD in Saline
Solubility: 2.86 mg/mL (11.81 mM); Clear solution; Need ultrasonic and warming

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.99%

Select Batch:

Data Sheet (285 KB) SDS (393 KB)

COA (255 KB) HNMR (252 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Li CJ, et al. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem. 1993 Oct 25;268(30):22463-8. [Content Brief]

[2]. Vanni A, et al. DNA damage and cytotoxicity induced by beta-lapachone: relation to poly(ADP-ribose) polymerase inhibition. Mutat Res. 1998 Jun 5;401(1-2):55-63. [Content Brief]

[3]. Kim TW, et al. β-Lapachone enhances Mre11-Rad50-Nbs1 complex expression in cisplatin-induced nephrotoxicity. Pharmacol Rep. 2016 Feb;68(1):27-31. [Content Brief]

Kinase Assay ^[1]	DNA topoisomerase I is incubated in the presence or absence of drugs (including β-Lapachone), in 20 μL of relaxation buffer (50 mM Tris (pH 7.5). 50 mM KCl, 10 mM MgCl₂, 0.5 mM dithiothreitol, 0.5 mM EDTA, 30 μg/mL bovine serum albumin) for 30 min at 37°C. Reactions are stopped by adding 1% SDS and proteinase K (50 μg/mL). After an additional 1-h incubation at 37°C, the products are separated by electrophoresis in 1% agarose gel in TAE buffer (0.04 M tris acetate, 0.001 M EDTA). The gel is stained with ethidium bromide after electrophoresis. The photographic negative is scanned with an NIH image analysis system^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[4]	Cytotoxicity is measured by an MTT assay. IMR-32 and JCI cells are plated in 96-well microtiter plates at a concentration of 5.0 × 10⁴ (topotecan) or 2.5 × 10⁴ (β-lapachone) cells/well/100 µL medium 24 hr prior to addition of various concentrations of topotecan or β-lapachone. The cells are then incubated for 72 hr at 37°C in a CO₂ incubator. Cell proliferation is assessed using a Cell Proliferation Kit I. Experiments are performed using four independent cultures^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Male Balb/c mice are provided a commercial pellet diet and water ad libitum. After 1 week of acclimation, the mice are randomly allocated to one of the following groups (5 per group): control, β-lapachone, cisplatin (18 mg/kg, ip), and β-lapachone + cisplatin (18 mg/kg, ip). The β-lapachone groups are fed a diet containing the drug (0.066) for 2 weeks prior to cisplatin injection. All mice are sacrificed under carbon dioxide anesthesia 3 days after cisplatin injection. The blood samples are subjected to serum BUN and CRE analyses. Half of the kidney is quickly removed for histopathological and immunohistochemical (IHC) studies. The other half is stored at −70°C until western blot assay^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Li CJ, et al. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem. 1993 Oct 25;268(30):22463-8. [Content Brief] [2]. Vanni A, et al. DNA damage and cytotoxicity induced by beta-lapachone: relation to poly(ADP-ribose) polymerase inhibition. Mutat Res. 1998 Jun 5;401(1-2):55-63. [Content Brief] [3]. Kim TW, et al. β-Lapachone enhances Mre11-Rad50-Nbs1 complex expression in cisplatin-induced nephrotoxicity. Pharmacol Rep. 2016 Feb;68(1):27-31. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	4.1276 mL	20.6381 mL	41.2763 mL	103.1907 mL
	5 mM	0.8255 mL	4.1276 mL	8.2553 mL	20.6381 mL
	10 mM	0.4128 mL	2.0638 mL	4.1276 mL	10.3191 mL
	15 mM	0.2752 mL	1.3759 mL	2.7518 mL	6.8794 mL
	20 mM	0.2064 mL	1.0319 mL	2.0638 mL	5.1595 mL
	25 mM	0.1651 mL	0.8255 mL	1.6511 mL	4.1276 mL
	30 mM	0.1376 mL	0.6879 mL	1.3759 mL	3.4397 mL
DMSO	40 mM	0.1032 mL	0.5160 mL	1.0319 mL	2.5798 mL
	50 mM	0.0826 mL	0.4128 mL	0.8255 mL	2.0638 mL
	60 mM	0.0688 mL	0.3440 mL	0.6879 mL	1.7198 mL
	80 mM	0.0516 mL	0.2580 mL	0.5160 mL	1.2899 mL
	100 mM	0.0413 mL	0.2064 mL	0.4128 mL	1.0319 mL

β-Lapachone Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

β-Lapachone4707-32-8ARQ-501 NSC-26326ARQ501ARQ 501NSC26326NSC 26326NSC-26326Indoleamine 2,3-Dioxygenase (IDO)TopoisomeraseAutophagyApoptosisInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

β-Lapachone (Synonyms: ARQ-501; NSC-26326)

Customer Review

β-Lapachone Related Antibodies

10 Publications Citing Use of MCE β-Lapachone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

View All Topoisomerase Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

β-Lapachone Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

β-Lapachone Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report